aibio
Distress ·
Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts
A termination agreement ends the license and assigns the patents and know-how to Mineralys. Up to $255.0 million in commercial milestones still applies.
MLYS Mineralys Therapeutics, Inc.
Mineralys Therapeutics (MLYS) news MLYS offering and buyback news
Latest Mineralys Therapeutics news
- Financings
Mineralys prices $150 million stock offering at $26.50 to fund Tanabe royalty buyback
Mineralys sold 5,660,378 shares at $26.50, below the $28.85 last sale on June 2, 2026. The proceeds fund part of a $200.0 million upfront payment to buy back a royalty owed to Tanabe Pharma Corporation.
- Debt Financing
Mineralys signs up to $500.0 million senior secured term loan
Mineralys can draw $100.0 million at closing on a $500.0 million loan, while the next $150.0 million depends on FDA approval of lorundrostat, and it owes Tanabe a $200.0 million cash payment.
Mineralys Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $132.0 million | $168.6 million |
| Net income (loss) | -$154.7 million | -$177.8 million |
| Cash from operations | -$142.4 million | -$166.3 million |
| Cash and equivalents | $172.9 million | $114.1 million |
Questions about Mineralys Therapeutics
Has Mineralys Therapeutics raised money recently?
Our latest story on this, dated Jun 3, 2026: "Mineralys prices $150 million stock offering at $26.50 to fund Tanabe royalty buyback". The story links the filing or release it is based on. Read the story.
Does Mineralys Therapeutics have a share buyback?
Our latest story on this, dated Jun 3, 2026: "Mineralys prices $150 million stock offering at $26.50 to fund Tanabe royalty buyback". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Mineralys Therapeutics?
Mineralys Therapeutics, Inc. trades under the ticker MLYS on NASDAQ.
Where is Mineralys Therapeutics listed?
Mineralys Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Mineralys Therapeutics?
The SEC Central Index Key (CIK) for Mineralys Therapeutics, Inc. is 1933414. Its filings are on SEC EDGAR.
How many shares does Mineralys Therapeutics have outstanding?
88,406,885 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is Mineralys Therapeutics listed under?
Our directory records Mineralys Therapeutics, Inc. under United States.
What does Mineralys Therapeutics do?
Our directory classifies Mineralys Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Mineralys Therapeutics?
The ISIN recorded for Mineralys Therapeutics, Inc. is US6031701013.
Does aibio.space cover Mineralys Therapeutics?
aibio.space lists Mineralys Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Is Mineralys Therapeutics profitable?
Mineralys Therapeutics, Inc. reported a net loss of $154.7 million for the fiscal year ended Dec 31, 2025, and used $142.4 million of cash in operations, per its annual report to the SEC.
How much does Mineralys Therapeutics spend on research and development?
$132.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Mineralys Therapeutics have?
$138.3 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Mineralys Therapeutics (MLYS) stock news?
Our latest story on Mineralys Therapeutics, dated Oct 29, 2026: "Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts". A termination agreement ends the license and assigns the patents and know-how to Mineralys. Up to $255.0 million in commercial milestones still applies. Source.
Does Mineralys Therapeutics have debt, a term loan or convertible notes?
Our latest debt story, dated Jun 2, 2026: "Mineralys signs up to $500.0 million senior secured term loan". Mineralys can draw $100.0 million at closing on a $500.0 million loan, while the next $150.0 million depends on FDA approval of lorundrostat, and it owes Tanabe a $200.0 million cash payment. Source.
Investor discussion: Mineralys Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Mineralys Therapeutics, Inc.
- CIK
- 1933414
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- MLYS (Nasdaq)
- Fiscal year ends
- December 31
- Filer category
- <br>Emerging growth company
- Business address
- 150 N. RADNOR CHESTER ROAD, RADNOR, PA
- Phone
- (888) 378-6240
- Shares outstanding
- 88,406,885 as of 2026-08-03 (10-Q filed 2026-08-11)
Recent filings
Listing details
- Company
- Mineralys Therapeutics, Inc.
- Ticker
- MLYS
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US6031701013
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction